Company Name
Galecto Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN:
US36322Q1076
CIK:
0001800315
CUSIP:
36322Q107
Currency:
USD
Full Time Employees:
5
Phone:
45 70 70 52 10
Website:
https://galecto.com
Fiscal Year End:
December
IPO Date:
Oct 29, 2020
Description:
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Address:
Ole Maaloes Vej 3, Copenhagen, Denmark, 2200